Compare ACADIA Pharmaceuticals Inc. (ACAD) vs MPLX LP (MPLX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs MPLX LP — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.78 (market cap $4.49B), while MPLX LP trades at $56.91 (market cap $58.36B). The key difference: MPLX LP is far larger — about 13× ACADIA Pharmaceuticals Inc.'s market cap, and MPLX LP pays a 7.49% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | MPLX | |
|---|---|---|
Market Cap | $4.49B | $58.36B |
Sector | Health | Technology |
52-Week High | $28.06 | $59.17 |
52-Week Low | $20.06 | $47.80 |
Enterprise Value | $3.69B | $82.99B |
Dividend Yield | — | 7.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
MPLX trades at $56.97, down 0.33% on the day, with a bullish technical signal supported by moving averages and key indicators like ADX. Financially, the company reported strong 2025 results with $11.47B revenue and $4.91B net income, though Q1 2026 EPS missed expectations. Analyst consensus is strongly positive with a $60.60 price target, and the recent $1.08 dividend underscores its income appeal.
The outlook for MPLX remains favorable, driven by its high-yield dividend, stable cash flows from fee-based contracts, and strategic focus on natural gas and NGL services. Key risks include exposure to energy commodity volatility and high debt levels. Upside potential hinges on execution of growth projects and sustained distribution growth amid a supportive midstream environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →
